Spinogenix

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Dendritic spine densitySmall molecule
Alzheimer's DiseaseSchizophreniaAmyotrophic Lateral Sclerosis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Tazbentetol (SPG302)Phase 2/3Amyotrophic Lateral Sclerosis
Est. primary completion 2027-12-31 · NCT07325591 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 December 2025Topline resultSPG302Tazbentetol (SPG302) Phase 2a in Alzheimer's disease (NCT06427668): topline results presented at CTAD 2025
Spinogenix, Inc. · Source ↗
4 November 2025Topline resultSPG302SPG302 Phase 2a in ALS (NCT05882695): topline results, well tolerated over 6 months
Spinogenix, Inc. · Source ↗

Financial reports

No financial reports recorded.